Gain Therapeutics (GANX) Non-Current Assets (2020 - 2026)

Gain Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $452191.0 in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 14.24% year-over-year to $452191.0 in Q2 2026; TTM through Jun 2026 was $452191.0, a 14.24% decrease from a year earlier, with the FY2025 full-year figure at $581837.0, up 11.59% from the prior year.
• Non-Current Assets was $452191.0 for Q2 2026 at Gain Therapeutics, down from $516696.0 in the prior quarter.
• The five-year high for Non-Current Assets was $6.1 million in Q2 2022, with the low at $452191.0 in Q2 2026.
• Average Non-Current Assets over 5 years is $1.4 million, with a median of $685984.5 recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 495.07% in 2022, then slumped 84.28% in 2023.
• Over 5 years, Non-Current Assets stood at $3.0 million in 2022, then slumped by 72.39% to $830463.0 in 2023, then tumbled by 37.22% to $521406.0 in 2024, then climbed by 11.59% to $581837.0 in 2025, then retreated by 22.28% to $452191.0 in 2026.
• The last three Non-Current Assets figures came in at $452191.0 (Q2 2026), $516696.0 (Q1 2026), and $581837.0 (Q4 2025), per Business Quant data.